Lilly's Garraway on his way to Roche as veteran Horning set to exit by year-end

Roche
This comes just twpo weeks after Garrway left Eli Lilly. (Roche)

Levi Garraway is set to take up one of the biggest hot seats in biopharma when he becomes the next chief medical officer and head of global product development at Roche in the fall.  

He will fill the large shoes left by the 10-year Roche-Genentech veteran Sandra Horning, who is retiring on the last day of this decade.

In a very brief release, the Swiss Big Pharma said that Garraway comes on board from the start of October, with the two working at the Big Pharma until December 31, when Horning officially leaves.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Garraway’s name will sound familiar as he was until very recently Eli Lilly’s SVP of oncology R&D, as well as heading up Lilly’s research laboratories novel target research. He will be based in South San Francisco.

RELATED: Eli Lilly cancer chief Levi Garraway replaced by Loxo CEO Josh Bilenker (for now) as Big Pharma rings the changes

He left unexpectedly at the start of the month “to pursue other opportunities” and it turns out it was a pretty big one.

Lilly has been working on cancer drugs and new therapies but with limited success; Roche is one of the largest oncology players on the planet with its older oncology medicines still raking in billions of dollars each year, though it now wants more of a say in the next-gen form of cancer care.

Suggested Articles

By employing heart rate signals, physical activity and sleep quality, common Fitbit trackers may be able to predict the spread of the flu.

Nanox has raised $26 million to help fuel the development and commercialization of its Star Trek-inspired digital X-ray bed.

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.